Carcinoembryonic antigen titers on effusion fluid. A diagnostic tool?

Carcinoembryonic antigen (CEA) has been demonstrated in tumors and body fluids, suggesting that effusion fluid (EF) CEA titer might separate benign and malignant EF. Plasma and EF CEA titers were determined on 141 patients with either benign (86) or malignant (55) EF. Although plasma CEA titers separated patients with either a benign or malignant EF 56% of the time, this separation was better accomplished (90% of the time) using EF CEA (P less than .

Carcinoembryonic antigen in cancer of the female reproductive system. Serial plasma values correlated with disease state.

The results of plasma carcinoembryonic antigen (CEA) determinations done over 600 patients with gynecologic malignancy will be presented. It would appear from this extensive survey that the likelihood of a patient having a positive value is increased with advancing stage and bulk of disease. The incidence of positive values in patients with clinical recurrence is quite impressive and presents a possible mode of follow-up for patients after standard treatment techniques have been administered for cervical cancer.

Carcinoembryonic antigen in patients with untreated central nervous system tumors.

This study was designed to determine whether immunological examination of carcinoembryonic antigen (CEA) levels in blood serum and cerebrospinal fluid would be helpful in detecting central nervous system tumors. Forty patients with tumors of the central nervous system were compared with 108 control patients. The findings suggest that: 1) CEA determinations are not helpful as a screening test in detecting preclinical central nervous system tumors; 2) Serum CEA determinations may be useful in determining the presence of a malignant tumor in patients with a circumscribed uptake on brain scan or a nonspecific mass lesion at cerebral angiography; 3) Cerebrospinal fluid CEA determinations were of no value in detecting central nervous system tumors; 4) Further study on a larger population of malignant central nervous system tumors is warranted.

Carcinoembryoinc antigen in cervical and vulvar cancer patients. Serum levels and disease progress.

Serial carcinoembryonic antigen (CEA) assays were performed on 10 patients with primary invasive squamous cell carcinoma of the cervix, 7 patients with recurrent squamous cell carcinoma of the cervix, and 5 patients with invasive squamous carcinoma of the vulva. Plasma CEA determinations were accomplished by radioimmunoassay, using a modification of Hanson's method. In 8 of the 10 patients with invasive squamous cell carcinoma of the cervix, positive CEA values dropped to normal ranges during the course of radiotherapy, usually in the first 4 weeks of treatment.

Carcinoembryonic antigen in patients with gynecologic malignancies.

The determination of carcinoembryonic antigen (CEA) in plasma has been of much interest currently concomitant with the search for an immunologic diagnosis test. Recent reports have shed some doubt on the specificity of carcinoembryonic antigens for gastrointestinal tract malignancies. This report details the plasma CEA values in 341 patients with varying gynecologic malignancies.